Increasing doses of pentoxifylline as a continuous infusion in canine septic shock

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 107-113

  Quezado, Zenaide M N ^a   Hoffman, William D ^a   Banks, Steven M ^a   Danner, Robert L ^a   Eichacker, Peter Q ^a   Susla, Gregory M ^a   Natanson, Charles ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; GRAM NEGATIVE SEPSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032962260     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bacher A, Mayer N, Klimscha W, Oismüller C, Steltzer H and Hammerle A (1997) Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 25:795-800.
2. Barton MH and Moore JN (1994) Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 44:216-220.
3. Bessler H, Gilgal R, Djaldetti M and Zahavi I (1986) Effect of pentoxifylline on the phagocytic activity, cAMP levels, and Superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 40:747-754.
4. Bienvenu J, Doche C, Gutowski M, Lenoble M, Lepape A and Perdrix J (1995) Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 25:S80-S84.
5. Carletto A, Biasi D, Bambara LM, Caramaschi P, Bonazzi ML, Lussignoli S, Andrioli G and Bellavite P (1997) Studies of skin-window exudate human neutrophils: Increased resistance to pentoxifylline of the respiratory burst in primed cells. Inflammation 21:191-203.
6. Castañon-Gonzalez A, Eid-Lidt G, Wacher N, Gallegos-Perez H and Miranda-Ruiz R(1995) Pentoxifylline and oxygen consumption in severe sepsis - A preliminary report. Acta Anaesthesiol Scand 39:219-222.
7. Cox DR (1995) Regression models and life-tables. JR Stat Soc 34:187-220, 1972.
8. D'Hellencourt CL, Diaw L, Cornillet P and Guenounou M (1996) Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 18:739-748.
9. Del Moral T, Goldberg RN, Suguihara C, Martinez O, Feuer WJ and Bancalari E (1996) Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet. Pediatr Res 31:596-600.
10. Doherty GM, Jensen JC, Alexander HR, Buresh CM and Norton JA (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198.
11. Eichacker PQ, Hoffman WD, Farese A, Danner RL, Suffredini AF, Waisman Y, Banks SM, Mouginis T, Wilson L, Rothlein R, Elin RJ, Hosseini JM, Macvittie TJ and Natanson C (1993) Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J Appl Physiol 74:1885-1892.
12. Eichacker PQ, Waisman Y, Natanson C, Farese A, Hoffman WD, Banks SM and Macvittie TJ (1994) Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of sepsis. J Appl Physiol 77:2366-2373.
13. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL and Natanson C (1992) Tumor necrosis factor challenges in canines: Patterns of cardiovascular dysfunction. Am J Physiol 263:H668-H675.
14. Flamand FJ, Sibbald WJ, Girotti MJ and Martin CM (1995) Pentoxifylline does not prevent microvascular injury in normotensive, septic rats. Crit Care Med 23:119-124.
15. Fletcher MA, Mckenna TM, Owens EH and Nadkarni VM (1992) Effects of in vivo pentoxifylline treatment on survival and ex vivo vascular contractility in a rat lipopolysaccharide shock model. Circ Shock 36:74-80.
16. Hadjiminas DJ, Mcmasters KM, Robertson SE and Cheadle WG (1994) Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1 beta expression but not inhibition of tumor necrosis factor synthesis. Surgery 116:348-355.
17. Hammerschmidt DE, Kotasek D, Mccarthy T, Huh PW, Freyburger G and Vercellotti GM (1988) Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 112:254-263.
18. Han, J., Thompson P and Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391-394.
19. Lambert WE, Yousouf MA, Van Liedekerke BM, de Roose JE and de Leenheer AP (1989) Simultaneous determination of pentoxifylline and three metabolites in biological fluids by liquid chromatography. Clin Chem 35:298-301.
20. Lauterbach R and Zembala M (1996) Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 155: 404-409.
21. Law WR, Nadkarni VM, Fletcher MA, Nevola JJ, Eckstein JM, Quance J, Mckenna TM, Lee CH and Williams TJ (1992) Pentoxifylline treatment of sepsis in conscious Yucatan minipigs. Circ Shock 37:291-300.
22. Lemay LG, Vander AJ and Kluger MJ (1990) The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL6), and tumor necrosis factor (TNF) in the rat. Cytokine 2:300-306.
23. Lundblad R, Ekstrom P and Giercksky KE (1995) Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 3:210-215.
24. Natanson C, Fink MP, Ballantyne HK, Macvittie TJ, Conklin JJ and Parrillo JE (1986) Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 78:259-270.
25. Natanson C (1997) Reevaluation of antiinflammatory trials in sepsis: A metaanalysis, in The American Thoracic Society Continuing Education Monograph Series, part II; Role of Cytokines in Systemic and Pulmonary Medicine (Nelson S ed) pp 7-18, American Lung Association, New York.
26. Netea MG, Blok WL, Kullberg B, Bemelmans M, Vogels MTE, Buurman WA and van der Meer JWM (1995) Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 171:393-399.
27. Noel P, Nelson S, Bokulic R, Bagby G, Lippton H, Lipscomb G and Summer W (1990) Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 47:1023-1029.
28. Puranapanda V, Hinshaw LB, O'Rear EA, Chang AC and Whitsett TL (1987) Erythrocyte deformability in canine septic shock and the efficacy of pentoxifylline and a leukotriene antagonist, proc Soc Exp Biol Med 185:206-210.
29. Ridings PC, Windsor AC, Sugerman HJ, Kennedy E, Sholley MM, Blocher CR, Fisher BJ and Fowler AA (1994) Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. Arch Surg 129:1144-1152.
30. Scheffe, H (1959) The Analysis of Variance, John Wiley & Sons Inc. New York.
31. Sevransky JE, Shaked G, Novogrodsky A, Levitzki A, Gazit A, Hoffman A, Elin RJ, Quezado ZM, Freeman BD, Eichacker PQ, Danner RL, Banks SM, Bacher J, Thomas ML, III and Natanson C (1997) Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest 99:1966-1973.
32. Siegel, S (1956) Nonparametric Statistics for the Behavioral Sciences, McGraw-Hill International Book Co., New York.
33. Sigurdsson GH and Youssef H (1993) Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock. Acta Anaesthesial Scand 37:396-403.
34. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E and Zabel P (1998) Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study. Arch Surg 133:94-100.
35. Strauss RE, Wertheim DL, Bonagura VR and Valacer DJ (1994) Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Pediatrics 93:205-210.
36. Sullivan GW, Carper HT, Novick WJ Jr and Mandell GL (1988) Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immunol 56:1722-1729.
37. Sullivan GW, Patselas TN, Redick JA and Mandell GL (1984) Enhancement of chemotaxis and protection of mice from infection. Trans Assoc Am Phys 97:337-345.
38. Van Leenen D, van der Poll T, Levi M, ten Cate H, van Deventer SJ, Hack CE, Aarden LA and ten Cate JW (1993) Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 151:2318-2325.
39. Ward A and Clissold S (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50-97.
40. Zeni F, Pain P, Vindimian M, Gay J, Gery P, Bertrand M, Page Y, Page D, Vermesch R and Bertrand J (1996) Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit Care Med 24:207-214.
41. Zeni F, Freeman B and Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095-1100.